fbpx An interview with Dr Rodríguez on what to discuss with patients and beyond | Progress In Mind

An interview with Dr Rodríguez on what to discuss with patients and beyond

Dr Alexandre González Rodríguez shares his experiences about the management of schizophrenia.

Q. When you first tell a patient they have schizophrenia, do you tell them this is a lifelong condition?

A. We tell them that the disease is chronic and needs long-term medication that can lead to normal functioning in some cases. Approximately 30% of patients achieve total remission, 30% partial remission and the remainder have treatment-resistant symptoms.

Q. Having made a diagnosis of schizophrenia – do you tell patients at that point how long they are likely to need to be on medication?

A. We tell our patients that the need for continued medication will be reassessed after 5 years.  Pharmacotherapy is given along with psychotherapy (cognitive behavioural therapy and cognitive remediation).

Q. What factors have a large contribution to the quality of life of a patient with schizophrenia?

A. Persistent, chronic symptoms adversely affect patients’ quality of life. Other factors to consider are compliance with medication, access to social support networks, insomnia (is common and is a big problem for patients), co-morbidity with substance abuse, employment status and marital status.

Q. What methods do you employ to preserve or improve the quality of life of your patients with schizophrenia?

A. Insomnia is treated and psychosocial therapy is given. Patients are monitored and their disease status is reassessed every 3-6 months using self-reporting methods and indirect methods, including urine analysis to ascertain both compliance with study medicines and any continuation of substance abuse.

Q. Do you think of schizophrenia as a neurodevelopmental disorder or as a neurodegenerative disease?

A. Both. There is evidence available to support both premises.

Q. What proportion of patients with schizophrenia have the potential to achieve improvements in relationships?

A. The earlier the patients are treated following onset of symptoms, the greater the improvement in their prognosis.  Up to 30% of patients show improvements, and 30% partial improvement, in their social skills and personal relationships.



The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country